Shikonin Modulates Cell Proliferation by Inducing Apoptosis in LLC Cells via MAPK Regulation and Caspase Activation

  • Lee, Soo-Jin (Department of Physiology, College of Oriental Medicine, Sangji University) ;
  • Kim, Sung-Hoon (Department of Oncology, Graduate School of East-West Medical Science, Kyunghee University)
  • Published : 2005.04.25

Abstract

Shikonin is a chemically characterized component of traditional herbal medicine, the root of Lithospermum erythrorhizon and has been shown to possess antitumor activities. Here we investigated anticancer potential of shikonin and its possible mechanism of action in LLC cells. Shikonin inhibited the proliferation of LLC cells in a concentration-dependent manner. It was also demonstrated that shikonin induced apoptosis in LLC cells by Annexin V staining and TUNEL staining analysis. Shikonin treatment was caused that decrease of Bcl-2, activation of caspases and cleavage of PARP. And shikonin also induced that the activation of mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38. Interestingly, the cell proliferation inhibition induced by shikonin was recovered by specific inhibitors of JNK and p38 but the inhibitor of MEK, the upstream kinase of ERK, did not recover. Additionally, shikonin administration at doses of 5 mg/kg in C57BL/6 mice strongly inhibited the primary tumor growth of LLC. Taken together, these results suggest that shikonin may suppress LLC cell proliferation by inducing an apoptotic process via activation of caspases and MAPKs

Keywords

References

  1. Thompson, C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462, 1995.
  2. Zornig, M., Hueber, A., Baum, W., Evan, G.. Apoptosis regulators and their role in tumorigenesis: Biochim Biophys Acta 1551, Fl-F37, 2001.
  3. Matsuzawa, A.,Ichijo, H. Molecular mechanisms of the decision between life and death: regulation of apoptosis by apoptosis signal-regulating kinase 1: J Biochem (Tokyo) 130, 1-8, 2001.
  4. Jacobson, M.D., Weil, M., Raff, M.C. Programmed cell death in animal development: Cell 88, 347-354, 1997.
  5. Kaufmann, S.H., Earnshaw, W.C. Induction of apoptosis by cancer chemotherapy: Exp Cell Res 256, 42-49, 2000.
  6. Bamford, M., Walkinshaw, G., Brown, R. Therapeutic applications of apoptosis research: Exp Cell Res 256, 1-11, 2000.
  7. Onishi, Y., Azurna, Y., Sato, Y., Mizuno, Y., Tadakurna. T., Kizaki, H. Topoisomerase inhibitors induce apoptosis in thymocytes: Biochim Biophys Acta 1175, 147-54, 1993.
  8. Bertrand, R., Solary, E., Jenkins, J., Pommier, Y. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors: Exp Cell Res 207, 388-397, 1993.
  9. Evans, D.L.,Dive, C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes: Cancer Res 53, 2133-2139 1993.
  10. Friesen, C. Herr, I., Krammer, P.H.,Debatin, K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2, 574-577, 1996.
  11. Bacus, S. S., Gudkov, A.V., Lowe, M., Lyass, J., Yung, Y., Komarov, A.P., Keyomarsi. K, Yarden, Y., Seger, R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53:Oncogene 20, 147-155, 2001.
  12. Xia, Z., Dickens, M., Raingeaud, L Davis, R.J., Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinascs on apoptosis: Science 270, 1326-1331, 1995.
  13. Sankawa, U., Ebizuka, Y., Miyazaki, T., Isomura, Y., Otsuka, H. Antitumor activity of shikonin and its derivatives:Chem Pharm Bull (Tokyo) 25, 2392-2395, 1977.
  14. Ozaki, Y., Ohno, A, Saito, Y.,Satake, M. Accelerative effect of shikonin, alkannin and acetylshikonin on the proliferation of granulation tissue in rats: Biol Pharm Bull 17, 1075-1077, 1994.
  15. Tanaka, S., Tajima, M., Tsukada, M.,Tabata, M. A comparative study on anti-inflammatory activities of the enantiomers, shikonin and alkannin: J Nat Prod 49, 466-469, 1986.
  16. Tanaka, Y., Odani, T. Pharmacodynamic study on 'Shiunko.' I. Antibacterial effect of 'Shiunko':Yakugaku Zasshi 92, 525-530, 1972.
  17. Yoon, Y., Kim, Y.O., Lim, N.Y., leon, W.K.,Sung, H.J. Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line: Planta Med 65, 532-535, 1999.
  18. Gao, D., Hiromura, M., Yasui, H.,Sakurai, H. Direct reaction between shikonin and thiols induces apoptosis in HL60 cells:Biol Pharm Bull 25, 827-832, 2002.
  19. Ahn, B.Z., Baik, K.U., Kweon, G..R., Lim, K, Hwang, B.D. Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I: J Med Chem 38, 1044-1047, 1995.
  20. Fujii, N., Yamashita, Y., Arima, Y., Nagashima, M.,Nakano, H. Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin: Antimicrob Agents Chemother 36, 2589-2594, 1992.
  21. Hashimoto, S., Xu, M., Masuda, Y., Aiuchi, T., Nakajo, S., Cao, J., Miyakoshi, M., Ida, Y., Nakaya, K beta-hydroxyisovalerylshikonin inhibits the cell growth of various cancer cell lines and induces apoptosis in leukemia HL-60 cells through a mechanism different from those of Fas and etoposide: J Biochem (Tokyo) 125, 17-23, 1999.
  22. Singh, E. Gao, D., Lebwohl, M.G.,Wei, H. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells:. Cancer Lett 200, 115-121, 2003.
  23. Guo, X.P., Zhang, X.Y.,Zhang, S.D. Clinical trial on the effects of shikonin mixture on later stage lung cancer: Zhong Xi Yi Jie He Za Zhi 11, 598-599, 580, 1991.
  24. Song, G..Y., Kim, Y, You, Y.J., Cho, H.,Ahn, B.Z. Naphthazarin derivatives (VII): antitumor action against ICR mice bearing ascitic 5-180 cells: Arch Pharm Res 24, 35-38, 2001.
  25. Ishiyama, M., Tominaga, H., Shiga, M., Sasamoto, K, Ohkura, Y., Ueno, K A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet: Biol Pharm Bull 19, 1518-1520, 1996.
  26. Nicholson, D.W. From bench to clinic with apoptosis-based therapeutic agents: Nature 407, 810-816, 2000.
  27. Oltvai, Z.N., Milliman, C.L.,Korsmeyer, S.J. &1-2 beterodirrerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death: Cell 74, 609-619, 1993.
  28. Zhu, X.F., Liu, Z.C.,; Xie, B.F., Li, Z.M., Feng, G.K, Xie, H.H., Wu, S.J. Yang, R.Z. Wei, X.Y., Zeng, Y.X, Involvement of caspase-3 activation in squamocin-induced apoptosis in leukemia cell line HL-60: Life Sci 70, 1259-1269, 2002.
  29. Lewis, T.S., Shapiro, P.S., Ahn, N.G. Signal transduction through MAP kinase cascades: Adv Cancer Res 74, 49-139, 1998.
  30. Chuang, S,M. Wang, I.C., Yang, J.L. Roles of JNK, p38 and ERK mitogen-activated protein kinases in the growth inhibition and apoptosis induced by cadmium: Carcinogenesis 21, 1423-1432, 2000.